ERBB2 and breast carcinoma: Low PRKAR1A/high SRC mRNA has been shown to define basal‐like and HER2‐positive breast cancers with a worse clinical outcome,3 and PKA activity has also been implicated in HER2 resistance in vitro, in particular down‐regulation of the PKA‐RIIα subunit.4